Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PredEver first: prednisone plus everolimus for newly diagnosed moderate or severe chronic GVHD
2011-004847-35Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- May 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and prednisone in chronic graft-versus-host disease (cGVHD), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Treatment success at 6 months. Started May 2012; status: completed.
02
Drugs
everolimusprednisone
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2011-004847-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004847-35.